Zacks Company Profile for BeiGene, Ltd. (BGNE : NSDQ) |
|
|
|
Company Description |
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.
Number of Employees: 8,200 |
|
|
|
Price / Volume Information |
Yesterday's Closing Price: $137.32 |
Daily Weekly Monthly
 |
20 Day Moving Average: 303,883 shares |
Shares Outstanding: 102.71 (millions) |
Market Capitalization: $14,103.62 (millions) |
Beta: 0.85 |
52 Week High: $426.56 |
52 Week Low: $120.00 |
Short Interest Ratio: |
|
% Price Change |
% Price Change Relative to S&P 500 |
4 Week |
-16.16% |
-8.20% |
12 Week |
-35.87% |
-27.92% |
Year To Date |
-49.31% |
-38.08% |
|
|
|
|
|
Address & Contact Information |
Street Address |
Phone / Fax |
Email Address |
Web URL |
94 SOLARIS AVENUE CAMANA BAY - GRAND CAYMAN,E9 KY1-1108 CYM |
ph: 1-345-949-4123 fax: - |
ir@beigene.com |
http://www.beigene.com |
|
|
|
General Corporate Information |
Officers
John V. Oyler - Chief Executive Officer and Chairman
Julia Wang - Chief Financial Officer
Timothy Chen - Director
Donald W. Glazer - Director
Margaret Dugan - Director
|
|
Peer Information
BeiGene, Ltd. (CORR.)
BeiGene, Ltd. (RSPI)
BeiGene, Ltd. (CGXP)
BeiGene, Ltd. (BGEN)
BeiGene, Ltd. (GTBP)
BeiGene, Ltd. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 07725L102
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/04/22
|
|
Share - Related Items
Shares Outstanding: 102.71
Most Recent Split Date: (:1)
Beta: 0.85
Market Capitalization: $14,103.62 (millions)
|
|
|
|
|
|
EPS Information |
Dividend Information |
Analyst Coverage: No |
Dividend Yield: 0.00% |
Current Fiscal Quarter EPS Consensus Estimate: $-4.38 |
Indicated Annual Dividend: $0.00 |
Current Fiscal Year EPS Consensus Estimate: $-15.13 |
Payout Ratio: |
Number of Estimates in the Fiscal Year Consensus: 5.00 |
Change In Payout Ratio: |
Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
Next EPS Report Date: 08/04/22 |
|
|
|
|